Why Viking Therapeutics Stock Crashed Today

Viking Therapeutics (NASDAQ: VKTX) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what pharmaceutical analysts are calling "mixed results" for its new GLP-1 weight loss pill, VK2735.

Image source: Getty Images.

In a press release this morning, Viking put a brave face on results of its "Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation." The study achieved primary and secondary endpoints, said Viking, "demonstrating statistically significant reductions [of 12.2%] in body weight with once-daily VK2735 dosing as compared to placebo." Weight loss continued after the 13 weeks were done, with no "plateau" observed in weight reduction post-study.

Source Fool.com